awmsg logo



tigecycline (Tygacil®)


Reference No. 2799

Publication date:
13/10/2015


Appraisal information

tigecycline (Tygacil®) 50 mg powder for solution for infusion


Company: Pfizer Ltd
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 09/10/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, tigecycline (Tygacil®) cannot be endorsed for use within NHS Wales in children from the age of eight years for the treatment of the following infections: complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections; complicated intra-abdominal infections (cIAI).
Statement of Advice (SOA)
Download